Fiona Kiely1,2, Alison Cran1,2, Deirdre Finnerty1,2, Tony O'Brien1,2. 1. 1 Department of Palliative Medicine, Marymount University Hospital & Hospice, Curraheen, Cork, Ireland. 2. 2 Department of Haematology, Dunmanway Day Unit, Cork University Hospital, Cork, Ireland.
Abstract
BACKGROUND: Knowledge of health-related quality of life (QoL) of patients with multiple myeloma on disease-modifying treatments is limited. AIM: (1) Determine symptom prevalence in patients with multiple myeloma on disease-modifying treatment. Identify the range and nature of these symptoms within the dimensions of physical, psychological, social, and financial well-being. (2) Measure self-reported QoL. (3) Compare the above-mentioned parameters to the general population and patients with advanced cancer. METHOD: Adults with multiple myeloma on disease-modifying treatment, attending the hematology day unit in a tertiary referral center from November 2012 to January 2013, were eligible for inclusion in a cross-sectional quantitative survey. Consenting patients completed 2 validated questionnaires, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) supplemented by the myeloma-specific module (EORTC QLQ-MY20) and the Hospital Anxiety Depression Score (HADS). RESULTS: Forty-one patients were included for analysis: 59% were male and 41% were female. Mean age was 63.7 years (range 46-86, standard deviation 11.24). The QoL scores were significantly lower than the general population and comparable to those with advanced cancer. The most commonly reported physical symptoms were pain (66%), fatigue (63%), and dyspnea (51%). About 54% of the patients were burdened by financial worries. Anxiety (30%) and depression (37%) were prevalent. CONCLUSION: Patients with myeloma on disease-modifying treatment have a lower QoL than the general population and are symptomatic across physical, psychological, financial, and social domains. A holistic approach to patient care is warranted, and patients may benefit from specialist palliative care input.
BACKGROUND: Knowledge of health-related quality of life (QoL) of patients with multiple myeloma on disease-modifying treatments is limited. AIM: (1) Determine symptom prevalence in patients with multiple myeloma on disease-modifying treatment. Identify the range and nature of these symptoms within the dimensions of physical, psychological, social, and financial well-being. (2) Measure self-reported QoL. (3) Compare the above-mentioned parameters to the general population and patients with advanced cancer. METHOD: Adults with multiple myeloma on disease-modifying treatment, attending the hematology day unit in a tertiary referral center from November 2012 to January 2013, were eligible for inclusion in a cross-sectional quantitative survey. Consenting patients completed 2 validated questionnaires, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) supplemented by the myeloma-specific module (EORTC QLQ-MY20) and the Hospital Anxiety Depression Score (HADS). RESULTS: Forty-one patients were included for analysis: 59% were male and 41% were female. Mean age was 63.7 years (range 46-86, standard deviation 11.24). The QoL scores were significantly lower than the general population and comparable to those with advanced cancer. The most commonly reported physical symptoms were pain (66%), fatigue (63%), and dyspnea (51%). About 54% of the patients were burdened by financial worries. Anxiety (30%) and depression (37%) were prevalent. CONCLUSION:Patients with myeloma on disease-modifying treatment have a lower QoL than the general population and are symptomatic across physical, psychological, financial, and social domains. A holistic approach to patient care is warranted, and patients may benefit from specialist palliative care input.
Authors: Thomas W LeBlanc; Christine S Ritchie; Fred Friedman; Janet Bull; Jean S Kutner; Kimberly S Johnson; Arif H Kamal Journal: J Pain Symptom Manage Date: 2016-11-01 Impact factor: 3.612
Authors: Evangelos Terpos; Joseph Mikhael; Roman Hajek; Ajai Chari; Sonja Zweegman; Hans C Lee; María-Victoria Mateos; Alessandra Larocca; Karthik Ramasamy; Martin Kaiser; Gordon Cook; Katja C Weisel; Caitlin L Costello; Jennifer Elliott; Antonio Palumbo; Saad Z Usmani Journal: Blood Cancer J Date: 2021-02-18 Impact factor: 11.037
Authors: Irena Cenzer; Karin Berger; Annette M Rodriguez; Helmut Ostermann; Kenneth E Covinsky Journal: Aging Clin Exp Res Date: 2020-01-22 Impact factor: 3.636
Authors: Sigrun Thorsteinsdottir; Gauti Gislason; Thor Aspelund; Ingigerdur Sverrisdottir; Ola Landgren; Ingemar Turesson; Magnus Björkholm; Sigurður Y Kristinsson Journal: Haematologica Date: 2019-12-02 Impact factor: 9.941